Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks.
Author(s): Brandes JL, Poole A, Kallela M, Schreiber CP, MacGregor EA, Silberstein SD, Tobin J, Shaw R
Affiliation(s): Nashville Neuroscience Group, PC, Vanderbilt University School of Medicine, Nashville, TN, USA 37203. firstname.lastname@example.org
Publication date & source: 2009-11, Cephalalgia., 29(11):1133-48.
Publication type: Research Support, Non-U.S. Gov't
The efficacy of a 6-day regimen of frovatriptan for menstrual migraine (MM; attacks starting on day -2 to +3 of menses) prevention in women with difficult-to-treat MM was assessed. Women with a documented inadequate response to triptans for acute MM treatment were included in this placebo-controlled, parallel-group trial. Women were randomized to double-blind treatment for three perimenstrual periods (PMPs) with either frovatriptan 2.5 mg (q.d. or b.i.d.) or placebo initiated 2 days before anticipated MM. The efficacy analysis included 410 women with 85% completing three double-blind PMPs. The mean number of headache-free PMPs was 0.92 with frovatriptan b.i.d., 0.69 with frovatriptan q.d. and 0.42 with placebo [P < 0.001 (b.i.d.) and P < 0.02 (q.d.) vs. placebo]. When migraine occurred, severity was reduced with frovatriptan q.d. (P < 0.001) and b.i.d. (P < 0.001) vs. placebo. Both frovatriptan regimens were well tolerated. In women with difficult-to-treat MM, a 6-day regimen of frovatriptan significantly reduced MM incidence and severity.